Equities research analysts expect Ra Pharmaceuticals Inc (NASDAQ:RARX) to announce ($0.48) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Ra Pharmaceuticals’ earnings, with estimates ranging from ($0.56) to ($0.43). Ra Pharmaceuticals reported earnings of ($0.61) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 21.3%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, May 8th.
According to Zacks, analysts expect that Ra Pharmaceuticals will report full-year earnings of ($2.10) per share for the current fiscal year, with EPS estimates ranging from ($2.32) to ($1.91). For the next financial year, analysts anticipate that the business will report earnings of ($2.40) per share, with EPS estimates ranging from ($2.74) to ($1.90). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.02. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $2.50 million.
Several equities analysts have weighed in on RARX shares. SunTrust Banks boosted their target price on shares of Ra Pharmaceuticals to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 11th. BMO Capital Markets set a $34.00 price objective on Ra Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 10th. ValuEngine upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Guggenheim assumed coverage on Ra Pharmaceuticals in a research note on Friday, February 22nd. They set a “buy” rating and a $48.00 target price for the company. Finally, BidaskClub upgraded Ra Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $36.50.
Institutional investors and hedge funds have recently made changes to their positions in the business. NEA Management Company LLC lifted its holdings in shares of Ra Pharmaceuticals by 11.7% in the 4th quarter. NEA Management Company LLC now owns 6,138,797 shares of the company’s stock worth $111,726,000 after acquiring an additional 645,161 shares during the last quarter. RA Capital Management LLC raised its position in Ra Pharmaceuticals by 26.1% in the fourth quarter. RA Capital Management LLC now owns 4,858,260 shares of the company’s stock valued at $33,963,000 after purchasing an additional 1,006,452 shares during the period. BlackRock Inc. lifted its stake in Ra Pharmaceuticals by 29.0% during the fourth quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock worth $48,142,000 after purchasing an additional 595,328 shares in the last quarter. First Manhattan Co. lifted its stake in Ra Pharmaceuticals by 35.4% during the fourth quarter. First Manhattan Co. now owns 1,453,724 shares of the company’s stock worth $26,457,000 after purchasing an additional 379,818 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its stake in Ra Pharmaceuticals by 102.1% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 879,000 shares of the company’s stock worth $15,997,000 after purchasing an additional 444,000 shares in the last quarter. Institutional investors and hedge funds own 90.00% of the company’s stock.
RARX stock traded up $0.75 during trading on Friday, reaching $23.51. 445,748 shares of the stock were exchanged, compared to its average volume of 655,411. Ra Pharmaceuticals has a 1 year low of $5.20 and a 1 year high of $27.68. The company has a market capitalization of $960.20 million, a PE ratio of -11.41 and a beta of 0.85.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Featured Article: What are the Different Types of Leveraged Buyouts?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.